Last reviewed · How we verify
Eplerenone vs Amlodipine
This is a comparison of two marketed cardiovascular drugs: eplerenone, a selective aldosterone antagonist, and amlodipine, a calcium channel blocker, each working through different pathways to lower blood pressure.
This is a comparison of two marketed cardiovascular drugs: eplerenone, a selective aldosterone antagonist, and amlodipine, a calcium channel blocker, each working through different pathways to lower blood pressure. Used for Hypertension (both agents), Heart failure with reduced ejection fraction (eplerenone), Post-myocardial infarction with left ventricular dysfunction (eplerenone).
At a glance
| Generic name | Eplerenone vs Amlodipine |
|---|---|
| Sponsor | Brigham and Women's Hospital |
| Drug class | Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine) |
| Target | Mineralocorticoid receptor (eplerenone); L-type voltage-gated calcium channel (amlodipine) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Eplerenone blocks aldosterone receptors in the kidney and heart, reducing sodium retention and blood volume while providing cardiac protection in heart failure and post-MI settings. Amlodipine blocks L-type calcium channels in vascular smooth muscle, causing vasodilation and reducing peripheral vascular resistance to lower blood pressure. These agents represent different mechanistic approaches to hypertension and cardiovascular disease management.
Approved indications
- Hypertension (both agents)
- Heart failure with reduced ejection fraction (eplerenone)
- Post-myocardial infarction with left ventricular dysfunction (eplerenone)
- Angina pectoris (amlodipine)
Common side effects
- Hyperkalemia
- Gynecomastia
- Peripheral edema
- Headache
- Flushing
- Dizziness
Key clinical trials
- Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eplerenone vs Amlodipine CI brief — competitive landscape report
- Eplerenone vs Amlodipine updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI